Medtronic Inc., an active acquirer and financial backer of new medical technologies, has moved its tax domicile overseas with the $42.9 billion acquisition of rival Covidien PLC, a deal that Medtronic says will free up billions of dollars that can be more easily and flexibly deployed to technologies being developed in the U.S.
Medtronic headquarters in Minneapolis Bloomberg News But investors in these U.S.-based technologies see things differently. The merger means that the medical-technology industry is consolidating, several venture capitalists said, which takes options off the table for young companies struggling to bring new treatments onto the market.
{iframe}http://blogs.wsj.com/venturecapital/2014/06/20/medtronic-covidien-merger-not-great-news-for-startups-vcs-say/?mod=startupjournal{/iframe}